Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation

Ji Won Kim; Byung Su Kim; Soo Mee Bang; Inho Kim; Dong Hwan Kim; Won Seog Kim; Deok Hwan Yang; Je Jung Lee; Je Hwan Lee; Jin Seok Kim; Sang Kyun Sohn; Ho Young Yhim; Jae Yong Kwak; Sung Soo Yoon; Jong Seok Lee; Seonyang Park; Byoung Kook Kim

doi:10.1007/s00277-011-1227-y

Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation

Ji Won Kim, Byung Su Kim, Soo Mee Bang, Inho Kim, Dong Hwan Kim, Won Seog Kim, Deok Hwan Yang, Je Jung Lee, Je Hwan Lee, Jin Seok Kim, Sang Kyun Sohn, Ho Young Yhim, Jae Yong Kwak, Sung Soo Yoon, Jong Seok Lee, Seonyang Park, Byoung Kook Kim

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

There are few treatment options for patients with non-Hodgkin lymphoma (NHL) who experienced progression after high-dose chemotherapy (HDC) with autologous stem cell transplantation (auto-SCT). The role of allogeneic stem cell transplantation (allo-SCT) in these patients has not been clarified yet. In this study, we report clinical outcomes of allo-SCT in patients with NHL who experienced progression after HDC with auto-SCT. Patients were enrolled from seven hospitals in Korea. A total of 38 patients were included: 18 patients (47.4%) underwent myeloablative conditioning and 20 patients (52.6%) reduced intensity conditioning. Overall response rate was 73.3%. Median event-free survival was 6.3 months. Median overall survival (OS) was 19.0 months. Estimated 5-year survival rate was 35.0%. Acute graft-versus-host disease developed in 13 patients (34.2%). Transplant-related mortality (TRM) was 21.1% (eight patients). Ann Arbor stage (p = 0.022), performance status (p < 0.001), and baseline serum albumin level (p = 0.010) were significant risk factors for OS. Performance status (p = 0.022) was a significant risk factor for TRM. Eight patients with persistent or progressive disease received donor lymphocyte infusion, and two of them achieved complete remission. In conclusion, despite high TRM, allo-SCT is a viable option for patients with NHL who underwent progression after HDC with auto-SCT.

Original language	English
Pages (from-to)	1409-1418
Number of pages	10
Journal	Annals of Hematology
Volume	90
Issue number	12
DOIs	https://doi.org/10.1007/s00277-011-1227-y
Publication status	Published - 2011 Dec

Bibliographical note

Funding Information:
Acknowledgments The authors wish to acknowledge the efforts of Ms. Eun Mi Kim and Ms. Su Jin Kim in the Seoul National University Hospital and Ms. Yoonjung Lee in the Severance Hospital for coordinating the procedure of transplantation. This study was supported by a grant of the Korea Health 21 R&D project, Ministry of Health and Welfare, Korea (A030001) and a grant of the Korea Health 21 R&D project, Ministry for Health and Welfare, Korea (A084783).

All Science Journal Classification (ASJC) codes

Hematology

Access to Document

10.1007/s00277-011-1227-y

Cite this

Kim, J. W., Kim, B. S., Bang, S. M., Kim, I., Kim, D. H., Kim, W. S., Yang, D. H., Lee, J. J., Lee, J. H., Kim, J. S., Sohn, S. K., Yhim, H. Y., Kwak, J. Y., Yoon, S. S., Lee, J. S., Park, S., & Kim, B. K. (2011). Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation. Annals of Hematology, 90(12), 1409-1418. https://doi.org/10.1007/s00277-011-1227-y

@article{d5d91899c2424851b1f9c44de8ff2d45,

title = "Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation",

abstract = "There are few treatment options for patients with non-Hodgkin lymphoma (NHL) who experienced progression after high-dose chemotherapy (HDC) with autologous stem cell transplantation (auto-SCT). The role of allogeneic stem cell transplantation (allo-SCT) in these patients has not been clarified yet. In this study, we report clinical outcomes of allo-SCT in patients with NHL who experienced progression after HDC with auto-SCT. Patients were enrolled from seven hospitals in Korea. A total of 38 patients were included: 18 patients (47.4%) underwent myeloablative conditioning and 20 patients (52.6%) reduced intensity conditioning. Overall response rate was 73.3%. Median event-free survival was 6.3 months. Median overall survival (OS) was 19.0 months. Estimated 5-year survival rate was 35.0%. Acute graft-versus-host disease developed in 13 patients (34.2%). Transplant-related mortality (TRM) was 21.1% (eight patients). Ann Arbor stage (p = 0.022), performance status (p < 0.001), and baseline serum albumin level (p = 0.010) were significant risk factors for OS. Performance status (p = 0.022) was a significant risk factor for TRM. Eight patients with persistent or progressive disease received donor lymphocyte infusion, and two of them achieved complete remission. In conclusion, despite high TRM, allo-SCT is a viable option for patients with NHL who underwent progression after HDC with auto-SCT.",

author = "Kim, {Ji Won} and Kim, {Byung Su} and Bang, {Soo Mee} and Inho Kim and Kim, {Dong Hwan} and Kim, {Won Seog} and Yang, {Deok Hwan} and Lee, {Je Jung} and Lee, {Je Hwan} and Kim, {Jin Seok} and Sohn, {Sang Kyun} and Yhim, {Ho Young} and Kwak, {Jae Yong} and Yoon, {Sung Soo} and Lee, {Jong Seok} and Seonyang Park and Kim, {Byoung Kook}",

note = "Funding Information: Acknowledgments The authors wish to acknowledge the efforts of Ms. Eun Mi Kim and Ms. Su Jin Kim in the Seoul National University Hospital and Ms. Yoonjung Lee in the Severance Hospital for coordinating the procedure of transplantation. This study was supported by a grant of the Korea Health 21 R&D project, Ministry of Health and Welfare, Korea (A030001) and a grant of the Korea Health 21 R&D project, Ministry for Health and Welfare, Korea (A084783).",

year = "2011",

month = dec,

doi = "10.1007/s00277-011-1227-y",

language = "English",

volume = "90",

pages = "1409--1418",

journal = "Annals of Hematology",

issn = "0939-5555",

publisher = "Springer Verlag",

number = "12",

}

Kim, JW, Kim, BS, Bang, SM, Kim, I, Kim, DH, Kim, WS, Yang, DH, Lee, JJ, Lee, JH, Kim, JS, Sohn, SK, Yhim, HY, Kwak, JY, Yoon, SS, Lee, JS, Park, S & Kim, BK 2011, 'Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation', Annals of Hematology, vol. 90, no. 12, pp. 1409-1418. https://doi.org/10.1007/s00277-011-1227-y

TY - JOUR

T1 - Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation

AU - Kim, Ji Won

AU - Kim, Byung Su

AU - Bang, Soo Mee

AU - Kim, Inho

AU - Kim, Dong Hwan

AU - Kim, Won Seog

AU - Yang, Deok Hwan

AU - Lee, Je Jung

AU - Lee, Je Hwan

AU - Kim, Jin Seok

AU - Sohn, Sang Kyun

AU - Yhim, Ho Young

AU - Kwak, Jae Yong

AU - Yoon, Sung Soo

AU - Lee, Jong Seok

AU - Park, Seonyang

AU - Kim, Byoung Kook

N1 - Funding Information: Acknowledgments The authors wish to acknowledge the efforts of Ms. Eun Mi Kim and Ms. Su Jin Kim in the Seoul National University Hospital and Ms. Yoonjung Lee in the Severance Hospital for coordinating the procedure of transplantation. This study was supported by a grant of the Korea Health 21 R&D project, Ministry of Health and Welfare, Korea (A030001) and a grant of the Korea Health 21 R&D project, Ministry for Health and Welfare, Korea (A084783).

PY - 2011/12

Y1 - 2011/12

N2 - There are few treatment options for patients with non-Hodgkin lymphoma (NHL) who experienced progression after high-dose chemotherapy (HDC) with autologous stem cell transplantation (auto-SCT). The role of allogeneic stem cell transplantation (allo-SCT) in these patients has not been clarified yet. In this study, we report clinical outcomes of allo-SCT in patients with NHL who experienced progression after HDC with auto-SCT. Patients were enrolled from seven hospitals in Korea. A total of 38 patients were included: 18 patients (47.4%) underwent myeloablative conditioning and 20 patients (52.6%) reduced intensity conditioning. Overall response rate was 73.3%. Median event-free survival was 6.3 months. Median overall survival (OS) was 19.0 months. Estimated 5-year survival rate was 35.0%. Acute graft-versus-host disease developed in 13 patients (34.2%). Transplant-related mortality (TRM) was 21.1% (eight patients). Ann Arbor stage (p = 0.022), performance status (p < 0.001), and baseline serum albumin level (p = 0.010) were significant risk factors for OS. Performance status (p = 0.022) was a significant risk factor for TRM. Eight patients with persistent or progressive disease received donor lymphocyte infusion, and two of them achieved complete remission. In conclusion, despite high TRM, allo-SCT is a viable option for patients with NHL who underwent progression after HDC with auto-SCT.

AB - There are few treatment options for patients with non-Hodgkin lymphoma (NHL) who experienced progression after high-dose chemotherapy (HDC) with autologous stem cell transplantation (auto-SCT). The role of allogeneic stem cell transplantation (allo-SCT) in these patients has not been clarified yet. In this study, we report clinical outcomes of allo-SCT in patients with NHL who experienced progression after HDC with auto-SCT. Patients were enrolled from seven hospitals in Korea. A total of 38 patients were included: 18 patients (47.4%) underwent myeloablative conditioning and 20 patients (52.6%) reduced intensity conditioning. Overall response rate was 73.3%. Median event-free survival was 6.3 months. Median overall survival (OS) was 19.0 months. Estimated 5-year survival rate was 35.0%. Acute graft-versus-host disease developed in 13 patients (34.2%). Transplant-related mortality (TRM) was 21.1% (eight patients). Ann Arbor stage (p = 0.022), performance status (p < 0.001), and baseline serum albumin level (p = 0.010) were significant risk factors for OS. Performance status (p = 0.022) was a significant risk factor for TRM. Eight patients with persistent or progressive disease received donor lymphocyte infusion, and two of them achieved complete remission. In conclusion, despite high TRM, allo-SCT is a viable option for patients with NHL who underwent progression after HDC with auto-SCT.

UR - http://www.scopus.com/inward/record.url?scp=84355161831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84355161831&partnerID=8YFLogxK

U2 - 10.1007/s00277-011-1227-y

DO - 10.1007/s00277-011-1227-y

M3 - Article

C2 - 21468694

AN - SCOPUS:84355161831

SN - 0939-5555

VL - 90

SP - 1409

EP - 1418

JO - Annals of Hematology

JF - Annals of Hematology

IS - 12

ER -

Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this